Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-11-07 Annual Report
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
20-F
Annual Report FY 2025
2025-11-07 English
NT 20-F
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 Notification of Late Filing submitted to the SEC by Kazia Therapeutics Limited. It notifies the SEC that the company will not be able to file its Annual Report on Form 20-F for the fiscal year ended June 30, 2025, by the prescribed due date and requests an extension. The document does not contain the actual Annual Report or financial data but is a regulatory notification about the delay in filing. The document length is 4262 characters, which is relatively short and consistent with a notification form rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) rather than the Annual Report (10-K or 20-F) itself.
2025-10-31 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains an announcement of a collaboration and in-licensing agreement for a PD-L1 protein degrader program, including details of the agreement, development plans, and forward-looking statements. The document also includes a press release as an exhibit. There are no financial statements or comprehensive financial data presented, nor is this an annual or interim report. The document is primarily an update on a corporate collaboration and licensing agreement, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories such as Capital/Financing Update or M&A Activity. The document length is substantial (15,000 characters), and it is not merely an announcement of a report publication. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-10-07 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains an announcement of a collaboration and in-licensing agreement for a PD-L1 protein degrader program, including details of the agreement, forward-looking statements, and a press release. The document does not contain financial statements or detailed financial analysis, nor is it an earnings release or annual/interim report. It is primarily an update and announcement of a material business development event. Form 6-K filings are typically classified as Regulatory Filings (RNS) in the absence of other specific report types. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is not a brief announcement but a substantive regulatory filing.
2025-10-07 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer pursuant to SEC rules. It includes a prospectus supplement and announces a collaboration and in-licensing agreement for a new drug development program. The document contains detailed information about the agreement, the drug candidate, development plans, and financial terms related to the collaboration. It also incorporates a press release as an exhibit. The document is not an annual or interim financial report, earnings release, or management discussion. It is a regulatory filing providing material information about a significant business development and is filed as a Form 6-K, which is typically classified under Regulatory Filings (RNS). The document is substantive and not merely an announcement of a report publication, nor is it a certification or attestation. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-10-07 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Kazia Therapeutics Limited, which is a report of a foreign private issuer submitted pursuant to SEC rules. It announces a collaboration and in-licensing agreement with QIMR Berghofer for a PD-L1 degrader program, including financial terms and development plans. The document includes a press release as Exhibit 99.1 and forward-looking statements. There are no financial statements or detailed financial analysis present, and the document primarily serves as a regulatory announcement of a material business update. It is not an annual or interim report, earnings release, or detailed management discussion. The document fits the definition of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories.
2025-10-07 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.